Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan

Stock Information for Appili Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Appili Therapeutics Inc

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®(TM)
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.